Pharmaceutical Executive-02-26-2009

News Analysis
Pharmaceutical Executive

February 25, 2009

CV Therapeutics and Genetech rejected offers from big-name suitors. Are they playing hard to get or are they just not that into them?

News Analysis
Pharmaceutical Executive

February 25, 2009

A sign of the times or a rash decision? In an effort to curb unnecessary costs, Pfizer kills development of two late-stage products rather than sink more money into them.